Hunterase Neuro
Hunter Syndrome (MPS II) with neurological involvement
ApprovedActive
Key Facts
Indication
Hunter Syndrome (MPS II) with neurological involvement
Phase
Approved
Status
Active
Company
About Nanolek
Nanolek is a prominent, revenue-generating Russian biopharma player with a dual focus on vaccines and specialty therapeutics. The company has established a strong commercial footprint, ranking among the top 10 suppliers in Russia's state procurement market, and is actively advancing its R&D capabilities, notably in novel vaccines and treatments for orphan diseases. Its strategic priorities include import substitution, expanding its pediatric vaccine portfolio (including a first Russian HPV vaccine), and leveraging its integrated platform from research to GMP manufacturing.
View full company profile